CN107660150B - Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 - Google Patents

Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 Download PDF

Info

Publication number
CN107660150B
CN107660150B CN201680013699.2A CN201680013699A CN107660150B CN 107660150 B CN107660150 B CN 107660150B CN 201680013699 A CN201680013699 A CN 201680013699A CN 107660150 B CN107660150 B CN 107660150B
Authority
CN
China
Prior art keywords
seq
antibody
free
cdr2
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680013699.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107660150A (zh
Inventor
G·德尔瓦尔
E·席夫林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ab2 Bio SA
Original Assignee
Ab2 Bio SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab2 Bio SA filed Critical Ab2 Bio SA
Publication of CN107660150A publication Critical patent/CN107660150A/zh
Application granted granted Critical
Publication of CN107660150B publication Critical patent/CN107660150B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
CN201680013699.2A 2015-03-05 2016-03-03 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 Active CN107660150B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15157742 2015-03-05
EP15157742.6 2015-03-05
EP15158781 2015-03-12
EP15158781.3 2015-03-12
EP15186626.6 2015-09-24
EP15186626 2015-09-24
PCT/EP2016/054524 WO2016139297A1 (en) 2015-03-05 2016-03-03 Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases

Publications (2)

Publication Number Publication Date
CN107660150A CN107660150A (zh) 2018-02-02
CN107660150B true CN107660150B (zh) 2023-10-24

Family

ID=55453181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680013699.2A Active CN107660150B (zh) 2015-03-05 2016-03-03 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中

Country Status (17)

Country Link
US (4) US10882905B2 (https=)
EP (1) EP3265807A1 (https=)
JP (2) JP7274259B2 (https=)
KR (1) KR102511343B1 (https=)
CN (1) CN107660150B (https=)
AU (1) AU2016227644B2 (https=)
CA (1) CA2972689A1 (https=)
CL (1) CL2017002237A1 (https=)
CO (1) CO2017008940A2 (https=)
IL (1) IL253292B2 (https=)
MX (1) MX2017010919A (https=)
MY (1) MY194040A (https=)
PH (1) PH12017501402A1 (https=)
RU (1) RU2755691C2 (https=)
SG (1) SG11201706879UA (https=)
UA (1) UA128752C2 (https=)
WO (1) WO2016139297A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925928A (zh) * 2013-09-05 2023-04-07 Ab2生物股份有限公司 炎性疾病中的il-18结合蛋白(il-18bp)
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
CN111315395A (zh) 2017-09-06 2020-06-19 耶鲁大学 白细胞介素-18变体和使用方法
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
WO2020018364A1 (en) * 2018-07-16 2020-01-23 University Of Hawaii Anti-galectin-9 antibody and methods of use thereof
CN108929382B (zh) * 2018-07-20 2019-10-15 深圳市第三人民医院 一种抗serinc5的抗体及其应用
US12269874B2 (en) 2018-12-03 2025-04-08 mAbProtein Co., Ltd. Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof
JP7631203B2 (ja) 2019-01-18 2025-02-18 ユニバーシティ ヘルス ネットワーク Ｌｉｌｒｂ３結合分子とその使用
US12594330B2 (en) 2019-06-04 2026-04-07 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
CN112582058B (zh) * 2019-11-07 2022-04-01 广州医科大学 一种基于空气质量的慢阻肺发病预测方法及系统
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
TW202210511A (zh) * 2020-06-01 2022-03-16 美商阿法羅醫療股份有限公司 涉及il-18抗體之方法及治療
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
JP2023549257A (ja) 2020-11-18 2023-11-22 ノバルティス アーゲー Ｎｌｒｃ４－ｇｏｆインフラマソーム病の処置における使用のための二特異性抗体
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
MX2024007616A (es) * 2021-12-20 2024-09-04 Avalo Therapeutics Inc Métodos y tratamiento para la enfermedad de still de inicio en la edad adulta y la artritis idiopática juvenil de inicio sistemico que implica anticuerpos contra il-18.
CN120737196A (zh) * 2022-01-28 2025-10-03 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
CA3244428A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa IL-18 BINDING PROTEIN (IL-18BP) IN THE TREATMENT OF VEXAS SYNDROME
PE20251671A1 (es) * 2022-03-15 2025-06-30 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer
IL321948A (en) 2023-01-06 2025-09-01 Lassen Therapeutics Inc Anti-IL-18 BP antibodies
EP4646270A2 (en) 2023-01-06 2025-11-12 Alector LLC Anti-il18 binding protein antibodies and methods of use thereof
WO2026038145A1 (en) 2024-08-13 2026-02-19 Ab2 Bio Sa Il-18 binding protein (il-18bp) and methods of using same
CN119192356B (zh) * 2024-09-29 2025-05-27 华中农业大学 识别犬瘟热病毒h蛋白的单克隆抗体、检测试纸条及应用
CN119241693B (zh) * 2024-09-29 2025-05-27 华中农业大学 一种抗犬瘟热病毒的基因工程嵌合抗体及应用
CN120349409B (zh) * 2025-04-08 2026-03-17 生物岛实验室 Il-18bp纳米抗体及其制备方法与应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1352650A (zh) * 1999-03-19 2002-06-05 史密丝克莱恩比彻姆公司 用于治疗il－18介导疾病的重组il－18拮抗物
WO2002032374A3 (en) * 2000-10-18 2002-09-19 Immunex Corp Methods for treating il-18 mediated disorders
CN1404400A (zh) * 2000-02-21 2003-03-19 应用研究系统Ars股份公司 Il－18抑制剂的应用
CN1499982A (zh) * 2001-01-29 2004-05-26 Ӧ���о�ϵͳARS�ɷݹ�˾ Il-18抑制剂在治疗和/或预防心脏病中的应用
CN1535160A (zh) * 2001-05-25 2004-10-06 ����˹ó�׹ɷ����޹�˾ Il-18抑制剂在治疗或预防中枢神经系统损伤中的应用
CN1902229A (zh) * 2003-11-12 2007-01-24 艾博特公司 Il－18结合蛋白
CN101062415A (zh) * 2000-02-21 2007-10-31 应用研究系统Ars股份公司 Il－18抑制剂的应用
CN103339147A (zh) * 2010-12-20 2013-10-02 米迪缪尼有限公司 抗il-18抗体和其用途
CN105722858A (zh) * 2013-09-05 2016-06-29 Ab2生物股份有限公司 炎性疾病中的il-18结合蛋白(il-18bp)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
ATE190629T1 (de) 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
WO1996013590A2 (en) 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
TWI335336B (https=) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
EE05056B1 (et) 2000-05-05 2008-08-15 Applied Research Systems Ars Holding N.V. IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
ES2334773T3 (es) 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
SI1487541T1 (sl) * 2002-03-22 2009-02-28 Serono Lab Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
MXPA05003869A (es) * 2002-10-08 2005-06-22 Ares Trading Sa El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina.
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
DK1601776T3 (da) 2003-03-11 2008-10-13 Serono Lab Ekspressionsvektorer omfattende mCmV-IE2-promotoren
US20080076708A1 (en) 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
AU2011224023C1 (en) 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
WO2005087249A1 (ja) 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
CA2572921C (en) 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
EP1793859B1 (en) 2004-08-20 2009-03-25 Smithkline Beecham Corporation Treatment of oral and intestinal mucositis by administering human il-18
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DE602006021038D1 (de) 2005-09-15 2011-05-12 Univ Mcgill Verfahren zur diagnose eines ovarialkarzinoms
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
US10882905B2 (en) * 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1352650A (zh) * 1999-03-19 2002-06-05 史密丝克莱恩比彻姆公司 用于治疗il－18介导疾病的重组il－18拮抗物
CN1404400A (zh) * 2000-02-21 2003-03-19 应用研究系统Ars股份公司 Il－18抑制剂的应用
CN101062415A (zh) * 2000-02-21 2007-10-31 应用研究系统Ars股份公司 Il－18抑制剂的应用
WO2002032374A3 (en) * 2000-10-18 2002-09-19 Immunex Corp Methods for treating il-18 mediated disorders
CN1499982A (zh) * 2001-01-29 2004-05-26 Ӧ���о�ϵͳARS�ɷݹ�˾ Il-18抑制剂在治疗和/或预防心脏病中的应用
CN1535160A (zh) * 2001-05-25 2004-10-06 ����˹ó�׹ɷ����޹�˾ Il-18抑制剂在治疗或预防中枢神经系统损伤中的应用
CN1902229A (zh) * 2003-11-12 2007-01-24 艾博特公司 Il－18结合蛋白
CN103339147A (zh) * 2010-12-20 2013-10-02 米迪缪尼有限公司 抗il-18抗体和其用途
CN105722858A (zh) * 2013-09-05 2016-06-29 Ab2生物股份有限公司 炎性疾病中的il-18结合蛋白(il-18bp)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Diagnosis and management of adult onset Still’s;P Efthimiou;《Ann Rheum Dis》;20051011;第65卷;第564-572页 *
High circulating levels of free interleukin-18 in patients with active SLE;Daniela Novick;《Journal of Autoimmunity》;20101231;第34卷;第121-126页 *
Role of IL-18 in acute lung inflammation;J A Jordan;《J Immunol》;20011215;第167卷(第12期);第7060-7068页 *
Role of IL-18 in Acute Lung Inflammation;Jacqueline A. Jordan;《J Immunol》;20011231;第167卷;第7060-7068页 *

Also Published As

Publication number Publication date
US20210188968A1 (en) 2021-06-24
CN107660150A (zh) 2018-02-02
AU2016227644A1 (en) 2017-07-20
EP3265807A1 (en) 2018-01-10
IL253292B2 (en) 2023-05-01
RU2017134857A (ru) 2019-04-09
JP7274259B2 (ja) 2023-05-16
AU2016227644B2 (en) 2022-06-16
JP2021176860A (ja) 2021-11-11
WO2016139297A1 (en) 2016-09-09
RU2755691C2 (ru) 2021-09-20
NZ733897A (en) 2023-11-24
IL253292B1 (en) 2023-01-01
MX2017010919A (es) 2017-12-07
US11820817B2 (en) 2023-11-21
UA128752C2 (uk) 2024-10-16
US10882905B2 (en) 2021-01-05
KR102511343B1 (ko) 2023-03-17
RU2017134857A3 (https=) 2019-12-23
SG11201706879UA (en) 2017-09-28
KR20170121199A (ko) 2017-11-01
US11926663B2 (en) 2024-03-12
JP7818795B2 (ja) 2026-02-24
BR112017017076A2 (en) 2018-04-10
MY194040A (en) 2022-11-09
CA2972689A1 (en) 2016-09-09
US20200377586A1 (en) 2020-12-03
PH12017501402A1 (en) 2018-01-15
US20180127494A1 (en) 2018-05-10
CL2017002237A1 (es) 2018-03-09
US20240190952A1 (en) 2024-06-13
JP2018513116A (ja) 2018-05-24
CO2017008940A2 (es) 2017-11-10
IL253292A (en) 2017-09-28

Similar Documents

Publication Publication Date Title
CN107660150B (zh) Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
US20230250164A1 (en) IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases
RU2810206C1 (ru) Il-18-связывающий белок (il-18bp) и антитела при воспалительных заболеваниях
CA2922498C (en) Il-18 binding protein (il-18bp) in inflammatory diseases
BR112017017076B1 (pt) Uso de il-18bp
JP2025507007A (ja) Ｖｅｘａｓの治療におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）
HK1221726B (en) Il-18 binding protein (il-18bp) in inflammatory diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment